Annual FCF
-$10.55 M
+$17.86 M+62.87%
December 1, 2023
Summary
- As of February 7, 2025, ORMP annual free cash flow is -$10.55 million, with the most recent change of +$17.86 million (+62.87%) on December 1, 2023.
- During the last 3 years, ORMP annual FCF has fallen by -$1.97 million (-22.91%).
- ORMP annual FCF is now -327.06% below its all-time high of $4.65 million, reached on August 31, 2016.
Performance
ORMP Free Cash Flow Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly FCF
-$7.11 M
-$9.18 M-442.29%
September 1, 2024
Summary
- As of February 7, 2025, ORMP quarterly free cash flow is -$7.11 million, with the most recent change of -$9.18 million (-442.29%) on September 1, 2024.
- Over the past year, ORMP quarterly FCF has dropped by -$5.68 million (-400.07%).
- ORMP quarterly FCF is now -204.45% below its all-time high of $6.80 million, reached on August 31, 2016.
Performance
ORMP Quarterly FCF Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
TTM FCF
-$7.93 M
-$6.38 M-411.88%
September 1, 2024
Summary
- As of February 7, 2025, ORMP TTM free cash flow is -$7.93 million, with the most recent change of -$6.38 million (-411.88%) on September 1, 2024.
- Over the past year, ORMP TTM FCF has increased by +$2.62 million (+24.84%).
- ORMP TTM FCF is now -194.47% below its all-time high of $8.39 million, reached on November 30, 2016.
Performance
ORMP TTM FCF Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Free Cash Flow Formula
FCF = Cash From Operations − CAPEX
ORMP Free Cash Flow Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | +62.9% | -400.1% | +24.8% |
| 3 y3 years | -22.9% | +16.5% | +74.2% |
| 5 y5 years | +18.6% | -117.4% | +32.9% |
ORMP Free Cash Flow Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3-year | at high | +62.9% | -442.3% | +22.5% | -411.9% | +74.2% |
| 5 y | 5-year | -22.9% | +62.9% | -442.3% | +22.5% | -411.9% | +74.2% |
| alltime | all time | -327.1% | +62.9% | -204.4% | +22.5% | -194.5% | +74.2% |
Oramed Pharmaceuticals Free Cash Flow History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sep 2024 | - | -$7.11 M(-442.3%) | -$7.93 M(+411.9%) |
| Jun 2024 | - | $2.08 M(-240.5%) | -$1.55 M(-75.3%) |
| Mar 2024 | - | -$1.48 M(+4.0%) | -$6.28 M(-40.5%) |
| Dec 2023 | -$10.55 M(-62.9%) | -$1.42 M(+95.7%) | -$10.55 M(-39.7%) |
| Sep 2023 | - | -$726.00 K(-72.6%) | -$17.50 M(-8.6%) |
| Jun 2023 | - | -$2.65 M(-53.8%) | -$19.13 M(-23.4%) |
| Mar 2023 | - | -$5.75 M(-31.3%) | -$24.99 M(-12.1%) |
| Dec 2022 | -$28.41 M(+155.3%) | -$8.37 M(+254.4%) | -$28.41 M(+5.4%) |
| Sep 2022 | - | -$2.36 M(-72.2%) | -$26.95 M(-12.4%) |
| Jun 2022 | - | -$8.51 M(-7.2%) | -$30.75 M(+10.3%) |
| Mar 2022 | - | -$9.17 M(+32.9%) | -$27.88 M(+26.8%) |
| Dec 2021 | -$11.13 M(-48.4%) | - | - |
| Nov 2021 | - | -$6.90 M(+11.9%) | -$21.99 M(+2.0%) |
| Aug 2021 | -$21.56 M(+151.1%) | -$6.17 M(+9.4%) | -$21.56 M(+20.3%) |
| May 2021 | - | -$5.64 M(+71.8%) | -$17.92 M(+14.6%) |
| Feb 2021 | - | -$3.28 M(-49.2%) | -$15.64 M(-2.2%) |
| Dec 2020 | -$8.58 M(-31.5%) | - | - |
| Nov 2020 | - | -$6.46 M(+154.8%) | -$15.99 M(+27.7%) |
| Aug 2020 | -$12.52 M(-3.3%) | -$2.54 M(-24.4%) | -$12.52 M(-5.5%) |
| May 2020 | - | -$3.36 M(-7.5%) | -$13.25 M(-2.3%) |
| Feb 2020 | - | -$3.63 M(+21.0%) | -$13.56 M(+14.8%) |
| Nov 2019 | - | -$3.00 M(-8.3%) | -$11.81 M(-8.8%) |
| Aug 2019 | -$12.96 M(-11.6%) | -$3.27 M(-10.8%) | -$12.96 M(-9.6%) |
| May 2019 | - | -$3.66 M(+94.4%) | -$14.34 M(-1.0%) |
| Feb 2019 | - | -$1.88 M(-54.5%) | -$14.48 M(-9.9%) |
| Nov 2018 | - | -$4.14 M(-11.0%) | -$16.07 M(+9.6%) |
| Aug 2018 | -$14.66 M(+151.1%) | -$4.65 M(+22.2%) | -$14.66 M(+21.6%) |
| May 2018 | - | -$3.81 M(+9.4%) | -$12.06 M(+13.6%) |
| Feb 2018 | - | -$3.48 M(+27.5%) | -$10.62 M(+5.5%) |
| Nov 2017 | - | -$2.73 M(+33.1%) | -$10.06 M(+72.4%) |
| Aug 2017 | -$5.84 M(-225.7%) | -$2.05 M(-13.1%) | -$5.84 M(-293.6%) |
| May 2017 | - | -$2.36 M(-19.4%) | $3.02 M(-4.0%) |
| Feb 2017 | - | -$2.93 M(-295.4%) | $3.14 M(-62.6%) |
| Nov 2016 | - | $1.50 M(-78.0%) | $8.39 M(+80.7%) |
| Aug 2016 | $4.65 M(-193.9%) | $6.80 M(-404.8%) | $4.65 M(-245.9%) |
| May 2016 | - | -$2.23 M(-196.0%) | -$3.19 M(+70.6%) |
| Feb 2016 | - | $2.32 M(-203.3%) | -$1.87 M(-67.8%) |
| Nov 2015 | - | -$2.25 M(+118.8%) | -$5.79 M(+17.1%) |
| Aug 2015 | -$4.95 M | -$1.03 M(+12.5%) | -$4.95 M(+4.7%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| May 2015 | - | -$914.00 K(-43.0%) | -$4.72 M(-2.6%) |
| Feb 2015 | - | -$1.60 M(+14.5%) | -$4.85 M(+2.5%) |
| Nov 2014 | - | -$1.40 M(+74.3%) | -$4.73 M(+15.9%) |
| Aug 2014 | -$4.08 M(+20.0%) | -$804.00 K(-22.6%) | -$4.08 M(+14.7%) |
| May 2014 | - | -$1.04 M(-30.1%) | -$3.56 M(-0.4%) |
| Feb 2014 | - | -$1.49 M(+97.3%) | -$3.58 M(+6.3%) |
| Nov 2013 | - | -$753.00 K(+166.8%) | -$3.36 M(-1.2%) |
| Aug 2013 | -$3.40 M(+47.7%) | -$282.20 K(-73.2%) | -$3.40 M(-1.7%) |
| May 2013 | - | -$1.05 M(-17.2%) | -$3.46 M(+5.2%) |
| Feb 2013 | - | -$1.27 M(+60.5%) | -$3.29 M(+26.0%) |
| Nov 2012 | - | -$792.80 K(+132.1%) | -$2.61 M(+13.4%) |
| Aug 2012 | -$2.30 M(+34.8%) | -$341.60 K(-61.3%) | -$2.30 M(-3.4%) |
| May 2012 | - | -$883.70 K(+48.9%) | -$2.38 M(+14.1%) |
| Feb 2012 | - | -$593.60 K(+22.6%) | -$2.09 M(+23.3%) |
| Nov 2011 | - | -$484.10 K(+14.5%) | -$1.69 M(-0.8%) |
| Aug 2011 | -$1.71 M(+20.4%) | -$422.90 K(-28.1%) | -$1.71 M(+5.4%) |
| May 2011 | - | -$588.30 K(+196.4%) | -$1.62 M(+6.4%) |
| Feb 2011 | - | -$198.50 K(-60.2%) | -$1.52 M(-12.8%) |
| Nov 2010 | - | -$498.40 K(+48.8%) | -$1.75 M(+23.1%) |
| Aug 2010 | -$1.42 M(-37.7%) | -$335.00 K(-31.8%) | -$1.42 M(-10.6%) |
| May 2010 | - | -$491.30 K(+16.6%) | -$1.59 M(+20.7%) |
| Feb 2010 | - | -$421.40 K(+146.9%) | -$1.32 M(-4.2%) |
| Nov 2009 | - | -$170.70 K(-66.1%) | -$1.37 M(-39.7%) |
| Aug 2009 | -$2.28 M(+16.8%) | -$503.80 K(+129.5%) | -$2.28 M(-5.8%) |
| May 2009 | - | -$219.50 K(-54.1%) | -$2.42 M(-11.5%) |
| Feb 2009 | - | -$478.70 K(-55.4%) | -$2.73 M(+5.7%) |
| Nov 2008 | - | -$1.07 M(+66.6%) | -$2.58 M(+32.6%) |
| Aug 2008 | -$1.95 M(+217.9%) | -$645.00 K(+21.2%) | -$1.95 M(+29.7%) |
| May 2008 | - | -$532.20 K(+60.1%) | -$1.50 M(+23.6%) |
| Feb 2008 | - | -$332.50 K(-24.3%) | -$1.22 M(+28.4%) |
| Nov 2007 | - | -$439.30 K(+121.6%) | -$946.40 K(+54.9%) |
| Aug 2007 | -$613.00 K(+69.5%) | -$198.20 K(-19.1%) | -$611.00 K(-7.0%) |
| May 2007 | - | -$245.00 K(+283.4%) | -$657.10 K(+25.7%) |
| Feb 2007 | - | -$63.90 K(-38.5%) | -$522.60 K(+13.6%) |
| Nov 2006 | - | -$103.90 K(-57.5%) | -$460.20 K(+27.2%) |
| Aug 2006 | -$361.60 K(+795.0%) | -$244.30 K(+121.1%) | -$361.70 K(+208.1%) |
| May 2006 | - | -$110.50 K(+7266.7%) | -$117.40 K(+1601.4%) |
| Feb 2006 | - | -$1500.00(-72.2%) | -$6900.00(+27.8%) |
| Nov 2005 | - | -$5400.00 | -$5400.00 |
| Aug 2005 | -$40.40 K | - | - |
FAQ
- What is Oramed Pharmaceuticals annual free cash flow?
- What is the all time high annual FCF for Oramed Pharmaceuticals?
- What is Oramed Pharmaceuticals annual FCF year-on-year change?
- What is Oramed Pharmaceuticals quarterly free cash flow?
- What is the all time high quarterly FCF for Oramed Pharmaceuticals?
- What is Oramed Pharmaceuticals quarterly FCF year-on-year change?
- What is Oramed Pharmaceuticals TTM free cash flow?
- What is the all time high TTM FCF for Oramed Pharmaceuticals?
- What is Oramed Pharmaceuticals TTM FCF year-on-year change?
What is Oramed Pharmaceuticals annual free cash flow?
The current annual FCF of ORMP is -$10.55 M
What is the all time high annual FCF for Oramed Pharmaceuticals?
Oramed Pharmaceuticals all-time high annual free cash flow is $4.65 M
What is Oramed Pharmaceuticals annual FCF year-on-year change?
Over the past year, ORMP annual free cash flow has changed by +$17.86 M (+62.87%)
What is Oramed Pharmaceuticals quarterly free cash flow?
The current quarterly FCF of ORMP is -$7.11 M
What is the all time high quarterly FCF for Oramed Pharmaceuticals?
Oramed Pharmaceuticals all-time high quarterly free cash flow is $6.80 M
What is Oramed Pharmaceuticals quarterly FCF year-on-year change?
Over the past year, ORMP quarterly free cash flow has changed by -$5.68 M (-400.07%)
What is Oramed Pharmaceuticals TTM free cash flow?
The current TTM FCF of ORMP is -$7.93 M
What is the all time high TTM FCF for Oramed Pharmaceuticals?
Oramed Pharmaceuticals all-time high TTM free cash flow is $8.39 M
What is Oramed Pharmaceuticals TTM FCF year-on-year change?
Over the past year, ORMP TTM free cash flow has changed by +$2.62 M (+24.84%)